Development of an Inactivated Vaccine against SARS CoV-2.

Pavel, Shaikh Terkis Islam; Yetiskin, Hazel; Uygut, Muhammet Ali; Aslan, Ahmet Furkan; Aydin, Günsu; Inan, Öznur; Kaplan, Büsra; Ozdarendeli, Aykut

Pavel, Shaikh Terkis Islam; Yetiskin, Hazel; Uygut, Muhammet Ali; Aslan, Ahmet Furkan; Aydin, Günsu; Inan, Öznur; Kaplan, Büsra; Ozdarendeli, Aykut.

Afiliación

Pavel STI; Department of Microbiology, Medical Faculty, Erciyes University, Kayseri 38280, Turkey.
Yetiskin H; Vaccine Research, Development and Application Center, Erciyes University, Kayseri 38280, Turkey.
Uygut MA; Department of Microbiology, Medical Faculty, Erciyes University, Kayseri 38280, Turkey.
Aslan AF; Vaccine Research, Development and Application Center, Erciyes University, Kayseri 38280, Turkey.
Aydin G; Vaccine Research, Development and Application Center, Erciyes University, Kayseri 38280, Turkey.
Inan Ö; Department of Microbiology, Medical Faculty, Erciyes University, Kayseri 38280, Turkey.
Kaplan B; Vaccine Research, Development and Application Center, Erciyes University, Kayseri 38280, Turkey.
Ozdarendeli A; Department of Microbiology, Medical Faculty, Erciyes University, Kayseri 38280, Turkey.

Vaccines (Basel) ; 9(11)2021 Nov 02.

Article en En | MEDLINE | ID: mdl-34835197

Palabras clave

COVID-19 vaccine; ERUCoV-VAC; SARS-CoV-2; TURKOVAC; immunogenicity; inactivated vaccine; vaccine

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Turquía